SubscribeLists
Investors poured $4 billion into digital health in a single quarter. Most of it went to a handful of companies doing one unglamorous thing extremely well. These are the ten worth your attention.
https://cdn.prod.website-files.com/6a494c345c90bdaf071b56ce/6a4e6da79fefd250207f05e2_hts-audio-top-10-healthtech-startups-to-watch-v3-felix.mp3
Digital health startups raised $4 billion in the first quarter of 2026 alone. The strongest opening quarter since the pandemic peak.
Here is the part most people miss. Nearly 60% of that money went to just 12 companies.
The market is not spreading bets anymore. It is concentrating them. So the useful question is not which startups are raising. It is which ones are being chosen, and why. I went through the funding data, the hospital deployments and the product launches. These are the ten I would watch.
An AI medical search engine trained on peer-reviewed literature, now used by more than 40% of US physicians. It closed a $250 million Series D in January, its third round in under a year, and signed the first enterprise deal of its kind with Mount Sinai. I covered why that matters in my breakdown of the rounds that map where medicine goes next.
Why it matters: Whoever sits between a doctor and the evidence quietly shapes what gets prescribed for everyone.
Abridge went from a $5 million seed in 2020 to roughly $758 million in total funding. Its ambient documentation is now embedded natively in Epic and deployed across more than 100 health systems, including a 2,800-clinician rollout at WVU Medicine.
Why it matters: Documentation is the most universal pain point in medicine. Abridge picked the boring problem and owned it.
Commure raised at a $7 billion valuation to run revenue cycle work inside more than 130 large health systems. I wrote a full analysis of why its moat is the mess, not the model.
Why it matters: US healthcare burns roughly $1 trillion a year on admin. The company that automates it wins by default.
Apella's operating room AI logs surgical events automatically and has helped hospitals lift surgical volume about 5% without adding staff. The OR can drive up to 60% of a hospital's revenue, which is why its $80 million Series B landed so easily.
Why it matters: The fastest financial win in healthcare right now is a less wasted hour.
Hippocratic builds AI agents for non-diagnostic patient work like discharge follow-ups and medication reminders, tested against large panels of clinicians before release. It has become one of the most-watched names in clinical-adjacent AI.
Why it matters: The staffing crisis is structural. Agents that safely absorb routine calls free humans for actual care.
A US federal rule requires insurers to make prior authorization fully electronic by January 2027. Latent, a prior-auth pure-play, raised an $80 million Series A almost the moment that deadline became real.
Why it matters: Regulation is the strongest tailwind in healthtech. Latent is riding a legal requirement, not a trend.
Trase raised a $107 million seed led by ARCH Venture Partners in June. At Duke's cardiology division, its agents automated more than 5,000 monthly faxes and unlocked roughly $285,000 in annual staff capacity.
Why it matters: Healthcare still runs on fax machines. The company that kills the fax queue prints money.
Midi built a national virtual clinic for perimenopause and menopause, reached unicorn status, and now works with insurers covering 45 million women. Full story in my funding rounds breakdown.
Why it matters: The biggest untapped markets in health are the ones medicine dismissed for decades.
Daniel Ek's body-scanning clinics convert 80% of healthy customers into prepaid annual members. I broke down why the moat is the renewal rate, not the scanner.
Why it matters: Healthcare never knew how to make money from healthy people. Neko cracked it.
Founded by two Stanford graduates, Clair raised $11.6 million for a hormone-aware health monitor launching late 2026. Most wearables infer metrics designed around male physiology. Clair starts from the hormonal signals that shape everything else.
Why it matters: Half the population has been a wearables afterthought. That gap is a market.
No general chatbots. No platforms promising AI for everything. Every company here picked one specific, regulated, unglamorous corner of healthcare and went impossibly deep.
That is the whole playbook in 2026. Narrow and deep is beating broad and shiny, and the funding data proves it every quarter.
Which of these ten would you back with your own money? Subscribe free to The HealthTech Signal and follow how each of these bets plays out.
HealthTech news, AI, funding and research. Straight to your inbox. Free.